Overall, 19.4% of patients were treated with only lifestyle changes, 43.5 with antidiabetics with a high risk of hypoglycemia (23.0% with insulin, 17.8% with sulfonylureas, 6.7% with glinides), and 37.6% with antidiabetic drugs with a low risk of hypoglycemia (Table 1). This evidence concerns the gene INS and Hypoglycemia.